Earnings Update: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Reported And Analysts Are Trimming Their ForecastsSimplywall·Aug 7 at 06:53 AMSNDX+0.78%
Syndax Pharmaceuticals (SNDX) Stock Climbs On Revenue Strength As Losses PersistSimplywall·Aug 5 at 10:36 PMSNDX+0.78%
Syndax grants stock option awards for 59,250 shares to five new employeesPUBT·Aug 5 at 03:12 PMSNDX+0.78%
Edding Genor’s Jing Zhu Da Sub-Licensing Deal Collapses After Upstream License TerminationTip Ranks·Aug 5 at 10:08 AMSNDX+0.78%06998-4.41%
Syndax Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results. Also, HC Wainwright & Co. lowered its price target on the stock from $40 to $38.benzinga_article·Aug 5 at 08:00 AMSNDX+0.78%
Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $39, Implies 104% UpsideTradingView·Aug 5 at 04:20 AMSNDX+0.78%
Syndax 1H FY26 net loss narrows to $49.4 million; 2Q FY26 revenue rises 92% to $72.8 millionPUBT·Aug 4 at 03:16 PMSNDX+0.78%
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026Unusual Whales·Jul 28 at 06:04 AMSNDX+0.78%
Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top AnalystTip Ranks·Jul 20 at 02:57 AMSNDX+0.78%
Syndax: Expanding Pipeline and Upcoming Axatilimab IPF Data Support Buy Rating and $29 Price Target UpsideTip Ranks·Jul 15 at 08:55 AMSNDX+0.78%
SNDX: Multiple late-stage and novel assets drive growth, with key data readouts expected in 2024–2025Quartr·Jul 14 at 12:59 PMSNDX+0.78%
